These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11913510)

  • 21. Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA.
    Jump RL; Riggs MM; Sethi AK; Pultz MJ; Ellis-Reid T; Riebel W; Gerding DN; Salata RA; Donskey CJ
    Emerg Infect Dis; 2010 May; 16(5):827-9. PubMed ID: 20409374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routine disc diffusion antimicrobial susceptibility testing of Clostridium difficile and association with PCR ribotype 027.
    Holt HM; Danielsen TK; Justesen US
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2243-6. PubMed ID: 26319148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of agar dilution and broth microdilution methods for Clostridium difficile antimicrobial susceptibility testing.
    Igawa G; Casey M; Sawabe E; Nukui Y; Okugawa S; Moriya K; Koike R; Tohda S; Saito R
    J Glob Antimicrob Resist; 2016 Dec; 7():43-45. PubMed ID: 27598055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.
    Wilcox MH; Fawley W; Freeman J; Brayson J
    J Antimicrob Chemother; 2000 Oct; 46(4):551-6. PubMed ID: 11020251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile.
    Ackermann G; Tang-Feldman YJ; Schaumann R; Henderson JP; Rodloff AC; Silva J; Cohen SH
    Clin Microbiol Infect; 2003 Jun; 9(6):526-30. PubMed ID: 12848728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in Clostridium (Clostridioides) difficile PCR-Ribotype Distribution and Antimicrobial Resistance in a German Tertiary Care Hospital Over the Last 10 Years.
    Piepenbrock E; Stelzer Y; Berger F; Jazmati N
    Curr Microbiol; 2019 Apr; 76(4):520-526. PubMed ID: 30805700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.
    Ackermann G; Tang YJ; Kueper R; Heisig P; Rodloff AC; Silva J; Cohen SH
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2348-53. PubMed ID: 11451695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
    Nyc O; Tejkalova R; Kriz Z; Ruzicka F; Kubicek L; Matejkova J; Kuijper E; Krutova M
    Microb Drug Resist; 2017 Jul; 23(5):609-615. PubMed ID: 27860531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and association of macrolide-lincosamide-streptogramin B (MLS(B)) resistance with resistance to moxifloxacin in Clostridium difficile.
    Ackermann G; Degner A; Cohen SH; Silva J; Rodloff AC
    J Antimicrob Chemother; 2003 Mar; 51(3):599-603. PubMed ID: 12615860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
    von Eiff C; Peters G
    J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clostridium difficile disease and vancomycin--questionable clinical superiority.
    Tarchini G
    Clin Infect Dis; 2011 Jul; 53(2):212. PubMed ID: 21690637
    [No Abstract]   [Full Text] [Related]  

  • 33. A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole.
    Adler A; Miller-Roll T; Bradenstein R; Block C; Mendelson B; Parizade M; Paitan Y; Schwartz D; Peled N; Carmeli Y; Schwaber MJ
    Diagn Microbiol Infect Dis; 2015 Sep; 83(1):21-4. PubMed ID: 26116225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Geographical clustering of cases of infection with moxifloxacin-resistant Clostridium difficile PCR-ribotypes 012, 017 and 046 in Sweden, 2008 and 2009.
    Akerlund T; Alefjord I; Dohnhammar U; Struwe J; Noren T; Tegmark-Wisell K;
    Euro Surveill; 2011 Mar; 16(10):. PubMed ID: 21435322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibiotic resistance dynamics and isolation rate of staphylococci and enterococci from patients of reconstructive surgery units].
    Bogomolova NS; Bol'shakov LV; Kuznetsova SM; Oreshkina TD
    Antibiot Khimioter; 2011; 56(5-6):37-45. PubMed ID: 22145229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
    J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
    Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
    J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibilities of canine Clostridium difficile and Clostridium perfringens isolates to commonly utilized antimicrobial drugs.
    Marks SL; Kather EJ
    Vet Microbiol; 2003 Jun; 94(1):39-45. PubMed ID: 12742714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Failure of intravenous linezolid to treat Clostridium difficile associated diarrhea.
    Lazzarini L; De Lalla F
    J Chemother; 2003 Jun; 15(3):299-300. PubMed ID: 12868561
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.